23andMe Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:23andMe Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010853
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
23andMe Inc (23andMe) is a biotechnology research and information provider that offers tools for health and ancestry care. The company offers raw genetic data and ancestry-related genetic reports. It offers clinical development, research and development, ancestry services, commercialization services, and information of personal ancestry, genealogy and inherited traits. 23andMe’s ancestry services comprise ancestry composition, family tree tool, DNA relatives, maternal and paternal lineages, and neanderthal percentage. The company helps individuals to understand their genetic information using DNA analysis technologies and web-based interactive tools. It caters to students, clinicians, and developers. 23andMe is headquartered in Mountain View, California, the US.

23andMe Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
23andMe Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
23andMe Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
23andMe Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
23andMe Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
23andMe Inc, Medical Devices Deals, 2011 to YTD 2017 9
23andMe Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
23andMe Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
23andMe Raises USD250 Million in Venture Financing 11
23andMe Raises USD79.07 Million in Venture Financing 13
23andMe Raises Additional USD9 Million in Series C Financing 14
Partnerships 15
H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 15
Reset Therapeutics Enters into Research Agreement with 23andMe 16
23andMe Partners with Genentech 17
23andMe Inc – Key Competitors 18
23andMe Inc – Key Employees 19
23andMe Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Government and Public Interest 21
Feb 22, 2017: Celmatix and 23andMe Announce Launch of Fertility Research Community 21
Apr 05, 2016: New Effort by 23andMe Could Increase Diversity in Genetic Research 22
Product News 23
Aug 02, 2017: 23andMe Enrolling For First-of-its-Kind Study on Major Depressive and Bipolar Disorders 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
23andMe Inc, Pharmaceuticals & Healthcare, Key Facts 2
23andMe Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
23andMe Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
23andMe Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
23andMe Inc, Deals By Therapy Area, 2011 to YTD 2017 8
23andMe Inc, Medical Devices Deals, 2011 to YTD 2017 9
23andMe Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
23andMe Raises USD250 Million in Venture Financing 11
23andMe Raises USD79.07 Million in Venture Financing 13
23andMe Raises Additional USD9 Million in Series C Financing 14
H. Lundbeck Enters into Agreement with 23andMe and Milken Institute 15
Reset Therapeutics Enters into Research Agreement with 23andMe 16
23andMe Partners with Genentech 17
23andMe Inc, Key Competitors 18
23andMe Inc, Key Employees 19
23andMe Inc, Subsidiaries 20

★海外企業調査レポート[23andMe Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • FMR LLC:企業の戦略的SWOT分析
    FMR LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Orbus Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Orbus Therapeutics Inc (Orbus Therapeutics) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for the treatment of anaplastic astrocytoma, a rare kind of cancer afflicting the central nervous system. Eflornithine, a cytostatic agent, indicated for the treat …
  • Siluria Technologies Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Siluria Technologies Inc (Siluria) engaged in producing fuels and chemicals from natural gas and low value byproducts. Its products include modus - olefins to gasoline, and gemini - natural gas to ethylene. The company also involved in catalytic process to convert natural gas into liquid fue …
  • Eesti Energia AS:企業の戦略的SWOT分析
    Eesti Energia AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Autodesk Inc:企業の戦略・SWOT・財務情報
    Autodesk Inc - Strategy, SWOT and Corporate Finance Report Summary Autodesk Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Intarcia Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Intarcia Therapeutics Inc (Intarcia), formerly BioMedicines Inc, is a biopharmaceutical company that discovers, develops and commercializes drug therapies and reduces effects for chronic diseases. The company’s product candidate include ITCA 650 is in Phase III clinical trial. Its ITCA 650 i …
  • Energinet.dk:企業の戦略的SWOT分析
    Energinet.dk - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Libbey Inc (LBY):企業の財務・戦略的SWOT分析
    Libbey Inc (LBY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Aeroport Anapa:企業の戦略・SWOT・財務情報
    Aeroport Anapa - Strategy, SWOT and Corporate Finance Report Summary Aeroport Anapa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Leclanche SA (LECN):電力:M&Aディール及び事業提携情報
    Summary Leclanche SA (Leclanche) is a custom battery storage solutions provider. The company develops and manufactures energy storage systems with large format lithium-ion cells. It also offers batteries and storage systems including portable energy systems, accumulators, torches and chargers. The c …
  • Spotlight Innovation Inc (STLT):企業の財務・戦略的SWOT分析
    Summary Spotlight Innovation Inc (Spotlight Innovation), formerly American Exploration Corp is a developer of proprietary technologies designed to treat rare, emerging and neglected diseases. The company’s product pipeline includes drug candidates for the treatment of cancer derived from specialized …
  • Myovant Sciences Ltd (MYOV):製薬・医療:M&Aディール及び事業提携情報
    Summary Myovant Sciences Ltd (Myovant), a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops and commercializes new treatments for women’s diseases and endocrine disorders. The company’s products include relugolix, an oral small molecule that functions as a gonadotropin …
  • ADVA Optical Networking SE (ADV):企業の財務・戦略的SWOT分析
    ADVA Optical Networking SE (ADV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Anworth Mortgage Asset Corp (ANH):企業の財務・戦略的SWOT分析
    Summary Anworth Mortgage Asset Corp (Anworth) is a financial service provider that provides mortgage real estate investment services. The company invests in mortgage-backed securities on a leveraged basis. It operates through agency credit-backed securities and non-agency credit-backed securities. A …
  • Banco Santander SA:企業の戦略・SWOT・財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • University Hospitals:製薬・医療:M&Aディール及び事業提携情報
    Summary University Hospitals is a healthcare service provider that offers patient-centered medical care and education services. The center’s services include abdominal imaging, acupuncture, addiction recovery, advanced heart failure and transplant, bariatric surgery, behavioral pediatrics and psycho …
  • The AES Corp (AES):企業の財務・戦略的SWOT分析
    The AES Corp (AES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • BYD Co Ltd (1211):企業の財務・戦略的SWOT分析
    BYD Co Ltd (1211) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • TECT Aerospace, Inc.:企業の戦略・SWOT・財務情報
    TECT Aerospace, Inc. - Strategy, SWOT and Corporate Finance Report Summary TECT Aerospace, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Kawasaki Heavy Industries Ltd (7012):企業の財務・戦略的SWOT分析
    Kawasaki Heavy Industries Ltd (7012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆